Evidence map›Paper›PMID 33327406›Full record

ArticleCancers2020

Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor.

Eric C Umbreit, Bilal A Siddiqui, Michael J Hwang, Aron Y Joon, Tapati Maity, Mary E Westerman, Kelly W Merriman, Hussam Alhasson, Joma Uthup, Tao Guo and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Eric C UmbreitDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Bilal A SiddiquiDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-6806-1294
Michael J HwangDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Aron Y JoonDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Tapati MaityDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mary E WestermanDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Kelly W MerrimanDepartment of Tumor Registry, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hussam AlhassonDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Joma UthupDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Tao GuoDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Joseph A MooreDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
John F WardDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jose A KaramDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Christopher G WoodDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Louis L PistersDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Miao ZhangDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Shi-Ming TuDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
TRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8M
NCI NIH HHS P30 CA016672NCI NIH HHS T32 CA009666University of Texas MD Anderson Cancer Center CA016672
6 · The paper itself

Abstract

Although genetic changes may be pivotal in the origin of cancer, cellular context is paramount. This is particularly relevant in a progenitor germ cell tumor and its differentiated mature teratoma counterpart when it concerns tumor heterogeneity and cancer dormancy in subsequent second malignancies (subsequent malignant neoplasms (SMNs)). From our tumor registry database, we identified 655 testicular germ cell tumor (TGCT) patients who developed SMNs between January 1990 and September 2018. Of the 113 solid organ SMNs, 42 had sufficient tumor tissue available for fluorescence in situ hybridization (FISH) analysis of isochromosome 12p [i(12p)]. We identified seven additional patients for targeted DNA and RNA sequencing of teratomas and adjacent somatic transformation. Finally, we established cell lines from freshly resected post-chemotherapy teratomas and evaluated the cells for stemness expression by flow cytometry and by the formation of teratomas in a xenograft model. In our cohort, SMNs comprising non-germ cell tumors occurred about 18 years after a diagnosis of TGCT. Of the 42 SMNs examined, 5 (12%) contained i(12p) and 16 (38%) had 12p gain. When comparing a teratoma and adjacent somatic transformation, targeted DNA and RNA sequencing demonstrated high concordance. Studies of post-chemotherapy teratoma-derived cell lines revealed cancer-initiating cells expressing multipotency as well as early differentiation markers. For the first time, we demonstrated the prevalence of i(12p) in SMNs and the presence of progenitor cells embedded within mature teratomas after chemotherapy. Our findings suggest a progenitor stem-like cell of origin in SMN and TGCT and highlight the importance of cellular context in this disease.

Indexed as

cancer stem cellisochromosome 12psecond malignancysomatic transformationteratomatesticular cancer

Identifiers

PMID33327406
PMCPMC7764868
OpenAlexW3113054602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.